tetrabenazine, including the Phase III trial that proved central to its approval for HD, did not allay concerns, though evidence supporting increased depression and suicide has been mixed, and is often confounded by the risk of depression and suicide in the underlying condition for which tetrabenazine has been applied, including HD [6, 7] . Now Dorsey and colleagues provide evidence that tetrabenazine does not increase the rates of depression, suicidality, or suicide. Using data collected during the COHORT observational study of HD [8] , they demonstrated no excess of depression, suicidality, or suicide attempts in the patients taking tetrabenazine compared to those who did not. The authors point out a variety of limitations, most prominently inclusion of only those patients willing to enroll in COHORT, the potential that participating in the study may itself have decreased the chance of depression and suicidaility, and the nonrandom selection of which patients received tetrabenazine. In addition, "depression" and "suicidality" were defined based on answers to single questions in the UHDRS rather than on the basis of a more comprehensive examination. On the other hand, the study was comparatively large, with greater than 350 participant-years of tetrabenazine exposure.
While not definitive, Dorsey et al provides some reassurance that the risk of depression and suicidality from tetrabenazine may not be as great as previously feared. This is good news for the treatment of HD, and also for the off-label use of tetrabenazine in other dyskinesias. It will be interesting to determine the effect on depression and suicidality of compounds related to 
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